Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar details- 2023
-
26 min
1. Planning and response to COVID-19: lessons from China and South-East Asia- Prof. Annelies Wilder-Smith
- 2022
-
12 min
2. The emergence of the SARS-CoV-2 Omicron variant- Prof. Emma Thomson
-
14 min
3. How is Omicron different?- Prof. Emma Thomson
- 2021
-
14 min
-
15 min
5. Potential of ‘long-COVID’ in triggering chronic co-pathologies- Dr. İmdat Eroğlu
-
8 min
6. SARS-CoV-2 monoclonal antibody testing in vivo- Prof. Michael Diamond
-
17 min
7. mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals- Prof. E. John Wherry
-
12 min
8. SARS-CoV-2 variants: implications for immunity and vaccine development- Prof. Danny Altmann
-
14 min
-
11 min
10. SARS-COV-2 human monoclonal antibody therapy update- Prof. James Crowe
-
12 min
11. Emergence of blood clotting disorders resulting from COVID vaccines inoculations- Prof. Dr. Sabine Eichinger
-
9 min
12. SARS-CoV-2 evolution within and between individuals- Prof. Katia Koelle
-
10 min
13. Identifying SARS-CoV-2 proteases- Prof. Dr. Christa E. Müller
- Prof. Dr. Michael Gütschow
-
20 min
14. Genetic surveillance and the emergence of SARS-CoV-2 variants- Prof. Emma Thomson
-
16 min
15. The COVID-19 outbreak: April 2021 update- Prof. Jonathan Temte
-
15 min
16. ABO blood groups and SARS-CoV-2 susceptibility- Dr. Sean Stowell
-
20 min
17. Impact of COVID-19 on neuropsychiatric disorders and mental health- Prof. Anthony David
-
20 min
18. The immune system response to the SARS-CoV-2 virus: March 2021 update- Prof. Paul Klenerman
-
6 min
-
12 min
-
13 min
-
18 min
-
17 min
23. SARS-CoV-2 vaccine rollout campaigns- Prof. Luis Graca
-
11 min
-
15 min
25. Interspecies transmission of SARS-CoV-2- Dr. Dalan Bailey
-
12 min
26. Complement activation in COVID-19- Prof. Jeffrey Laurence
-
9 min
27. Human movement patterns and local spread of COVID-19- Prof. Ben Cowling
-
10 min
28. SARS-CoV-2 mutations: phenotypes and implications for vaccine development- Prof. David Montefiori
- 2020
-
18 min
29. The immune system response to the SARS-CoV-2 virus: December 2020 update- Prof. Paul Klenerman
-
20 min
30. Triage and end of life care planning in COVID-19- Prof. Robin Taylor
-
14 min
31. Natural killer cells as COVID-19 therapy- Dr. Philippa Kennedy
-
13 min
32. Update on the SNG001 drug, an INFβ therapy for COVID-19- Prof. Stephen Holgate
-
15 min
-
10 min
34. Identification of a new coronavirus-specific RNA export protein complex- Dr. Montse Bárcena-Martin
-
17 min
35. The neurological symptoms of COVID-19- Dr. Michael Zandi
-
12 min
36. Imperial College London’s saRNA Vaccine - COVAC1- Dr. Katrina Pollock
-
15 min
37. Interferon-α2b as a therapy for COVID-19- Prof. Eleanor N. Fish
-
11 min
38. Potential long-term health effects of a SARS-CoV-2 infection- Prof. Danny Altmann
-
12 min
39. The COVID-19 coronavirus outbreak: October 2020 update- Prof. Jonathan Temte
-
9 min
-
16 min
41. Rheumatic diseases and COVID-19- Dr. Zachary Wallace
-
17 min
42. The cardiovascular complications of SARS-CoV-2 infection- Prof. Srihari Naidu
-
20 min
43. Medical wearable devices for tracking symptoms of COVID-19- Prof. John Rogers
-
21 min
44. Risk of re-emergence of COVID-19 after exit from lockdown- Dr. Leonardo Lopez
-
16 min
45. The evolutionary origin of SARS-CoV-2- Dr. Feng Gao
-
15 min
46. Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge- Prof. Jordan Peccia
-
12 min
47. Approaches for elucidating genetic susceptibility to SARS-CoV-2- Dr. Kenneth Baillie
-
22 min
48. The immune system response to the SARS-CoV-2 virus: July 2020 update- Prof. Paul Klenerman
-
22 min
49. The impact of COVID-19 in the elderly and in care homes- Dr. David Strain
-
19 min
50. Human challenge trials for vaccines against COVID-19- Prof. Peter Smith
-
9 min
51. The development of SARS-CoV-2 vaccines- Prof. Peter Hotez
-
15 min
52. Convalescent plasma therapy as a treatment for COVID-19- Dr. Manu Shankar-Hari
-
12 min
53. Remdesivir COVID-19 clinical trial- Prof. Mahesh Parmar
-
17 min
54. Nanotechnologies in the fight against coronaviruses- Prof. Sabine Szunerits
-
15 min
55. The COVID-19 coronavirus outbreak: May 2020 update- Prof. Jonathan Temte
-
10 min
56. INFβ therapy for COVID-19: the new SNG001 drug- Prof. Stephen Holgate
-
12 min
57. Strategies for exiting the lockdown- Prof. David McCoy
-
17 min
58. SARS-CoV-2 human monoclonal antibody therapy- Prof. James Crowe
-
8 min
59. An FDA approved salivary test for SARS-CoV-2 infection- Prof. Andrew Brooks
-
15 min
60. Development of an intranasal vaccine for SARS-CoV-2- Dr. Scot Roberts
-
13 min
61. The immune system response to the SARS-CoV-2 virus: an update- Prof. Paul Klenerman
-
8 min
62. A novel AIOD-CRISPR system for diagnosis of SARS-CoV-2- Prof. Changchun Liu
-
20 min
63. Development of PRO-140 (Leronlimab) as a treatment for COVID-19- Dr. Jacob Lalezari
-
16 min
64. COVID-19 epidemiology and potential treatments: follow up interview- Prof. Ralph Baric
-
12 min
65. SARS-CoV-2 vaccine development: where are we now?- Prof. Gary Kobinger
-
13 min
66. SARS-CoV-2: What we need to know and possible future therapies- Prof. Stanley Perlman
-
8 min
67. SARS-CoV-2 vaccine: current biological targets and considerations- Dr. Adolfo Garcia-Sastre
-
20 min
68. The current understanding of the biology of the SARS-CoV-2 virus- Prof. Peter Palese
-
16 min
-
17 min
70. The immune system response to the SARS-CoV-2 virus- Prof. Paul Klenerman
-
9 min
71. SARS-CoV-2 vaccine development- Prof. Stanley Plotkin
-
12 min
72. The COVID-19 outbreak: an update on the SARS-CoV-2 virus- Prof. Ralph Baric
-
14 min
73. The COVID-19 coronavirus outbreak: a current view- Prof. Jonathan Temte
-
17 min
74. The COVID-19 coronavirus outbreak: March 2020 update- Prof. Jonathan Temte
Topics Covered
- Work done in the lab to test monoclonal antibody efficacy in vivo
- How the antibodies are chosen for testing
- Work done on possible future SARS-CoV-2 mutations
- Combating neutralisation escape
- Working towards broadly neutralising antibodies
- Future work for this research
Biography
Michael S. Diamond, MD, PhD, is the Herbert S. Gasser Professor of Medicine and a professor of molecular microbiology and of pathology and immunology at the Washington University School of Medicine. He is also an associate director for the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs. He is recognized internationally for his work involving Zika, West Nile, chikungunya, SARS-CoV-2, and other emerging RNA viruses, in which he seeks to understand how these viruses cause illness and interact with and evade the body’s defences.
During the summer of 2020 he developed the first mouse model of SARS-CoV-2, which subsequently facilitated the development of a nasal vaccine that prevented infection in mice, hamsters, and non-human primates. Diamond and his team also recently identified a receptor-decoy molecule that protects mice from brain infections caused by Venezuelan equine encephalitis virus (VEEV), a mosquito-borne virus notorious for causing fast-spreading, deadly outbreaks in Mexico, Central America and northern South America. This molecule could serve as a much-needed tool to control the deadly virus, which is expected to expand its range as the climate changes.
Dr. Diamond is an elected member of the American Society of Clinical Investigation, the American Association for the Advancement of Science, the Association of American Physicians, the American Society of Clinical Investigation, the National Academy of Inventors, and the National Academy of Medicine. He is a past Burroughs Wellcome Fund and Ellison Medical Foundation awards recipient, as well as a recipient of Stanley J. Korsmeyer Award of the American Society of Clinical Investigation. He is currently a member of the scientific advisory board of the Investigators in the Pathogenesis of Infectious Disease program at the Burroughs Wellcome Fund and an elected Councilor for the Association of American Physicians.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Diamond, M. (2021, August 12). SARS-CoV-2 monoclonal antibody testing in vivo [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 9, 2025, from https://doi.org/10.69645/XVHP7431.Export Citation (RIS)
Publication History
- Published on August 12, 2021
Financial Disclosures
- Prof. Michael Diamond has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
SARS-CoV-2 monoclonal antibody testing in vivo
Published on August 12, 2021
8 min
A selection of talks on Methods
Transcript
Please wait while the transcript is being prepared...
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)